- Associated Press•last month
The Rockville, Maryland-based company said it had a loss of 1 cent per share. The company's shares closed at 15 cents. A year ago, they were trading at 50 cents. _____ This story was generated by Automated ...
- GlobeNewswire•last month
Preliminary Efficacy Data from Phase Ib/IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer presented at European Society for Medical Oncology Congress. Initiates Stage 2 of the Phase IIa clinical ...
- GlobeNewswire•last monthRexahn Pharmaceuticals Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Patent Covering the Manufacturing of RX-3117 – A Cancer Cell Specific Anticancer Agent
ROCKVILLE, Md., Oct. 31, 2016-- Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that it has received ...
RNN : Summary for Rexahn Pharmaceuticals, Inc. Co - Yahoo Finance
Rexahn Pharmaceuticals, Inc. (RNN)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
|Bid||0.16 x 1000|
|Ask||0.16 x 16400|
|Day's Range||0.16 - 0.17|
|52 Week Range||0.14 - 0.45|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.81|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|